X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
maytansine - analogs & derivatives (457) 457
humans (386) 386
index medicus (319) 319
female (263) 263
trastuzumab (244) 244
maytansine - therapeutic use (200) 200
oncology (190) 190
breast neoplasms - drug therapy (185) 185
animals (176) 176
antibodies, monoclonal, humanized - therapeutic use (143) 143
maytansine - pharmacology (137) 137
antineoplastic agents - therapeutic use (135) 135
breast cancer (109) 109
mice (102) 102
maytansine - administration & dosage (95) 95
middle aged (95) 95
receptor, erbb-2 - metabolism (95) 95
breast neoplasms - pathology (94) 94
cancer (89) 89
maytansine - adverse effects (83) 83
maytansine - chemistry (76) 76
cell line, tumor (75) 75
pharmacology & pharmacy (75) 75
adult (74) 74
aged (74) 74
antibodies, monoclonal, humanized - administration & dosage (71) 71
chemotherapy (69) 69
trastuzumab emtansine (69) 69
antibodies, monoclonal, humanized - adverse effects (68) 68
t-dm1 (68) 68
treatment outcome (66) 66
antineoplastic agents - pharmacology (64) 64
antibodies, monoclonal, humanized - pharmacology (63) 63
maytansine (62) 62
maytansine - pharmacokinetics (60) 60
antineoplastic agents - adverse effects (58) 58
antibody-drug conjugate (56) 56
xenograft model antitumor assays (55) 55
breast neoplasms - metabolism (54) 54
metastasis (51) 51
her2 (50) 50
analysis (48) 48
antineoplastic combined chemotherapy protocols - therapeutic use (48) 48
breast-cancer (48) 48
immunoconjugates - therapeutic use (48) 48
therapy (48) 48
phase-ii (47) 47
maytansine - metabolism (45) 45
receptor, erbb-2 - genetics (44) 44
male (43) 43
care and treatment (42) 42
pertuzumab (42) 42
trastuzumab - therapeutic use (42) 42
antibodies, monoclonal, humanized - pharmacokinetics (41) 41
tumors (41) 41
antibodies (40) 40
biochemistry & molecular biology (40) 40
drug therapy (40) 40
antibodies, monoclonal - therapeutic use (39) 39
antineoplastic agents - administration & dosage (39) 39
monoclonal-antibody (39) 39
receptor, erbb-2 - antagonists & inhibitors (39) 39
neoplasms - drug therapy (37) 37
disease-free survival (36) 36
antineoplastic agents - pharmacokinetics (35) 35
article (35) 35
neoplasm metastasis (35) 35
antineoplastic agents (34) 34
breast neoplasms - genetics (34) 34
immunoconjugates - pharmacology (34) 34
lapatinib (34) 34
aged, 80 and over (33) 33
mice, nude (33) 33
research (33) 33
biopharmaceutics (32) 32
medicine & public health (32) 32
viral antibodies (32) 32
epidermal growth factor (31) 31
expression (31) 31
receptor, erbb-2 - analysis (31) 31
skin and connective tissue diseases (31) 31
survival (30) 30
antimitotic agents (29) 29
cell proliferation - drug effects (29) 29
clinical trials as topic (29) 29
monoclonal-antibodies (29) 29
erbb-2 protein (28) 28
hematology, oncology and palliative medicine (28) 28
immunoconjugates - chemistry (28) 28
pharmacokinetics (28) 28
biosynthesis (27) 27
efficacy (27) 27
tubulin - metabolism (27) 27
antitumor-activity (26) 26
breast neoplasms - mortality (26) 26
chemistry, multidisciplinary (26) 26
medicine, research & experimental (26) 26
metastatic breast-cancer (26) 26
pharmacology/toxicology (26) 26
antineoplastic agents - chemistry (25) 25
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 19, pp. 1783 - 1791
Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to... 
CAPECITABINE | LAPATINIB | MEDICINE, GENERAL & INTERNAL | THERAPY | PHASE-II | ANTIBODY | RECEPTOR | PLUS | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Trastuzumab | Drugs | Dose-response relationship (Biochemistry) | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Comparative analysis | Thrombocytopenia | Chemotherapy | Epidermal growth factor | Vomiting | Diarrhea | Cytotoxicity | Nausea | Survival | ErbB-2 protein | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2012, Volume 30, Issue 26, pp. 3234 - 3241
Journal Article
Natural Product Research, ISSN 1478-6419, 09/2013, Volume 27, Issue 17, pp. 1532 - 1536
By using various column chromatography for purification, two new compounds of ansamitocin (1 and 2) were isolated from the extracts of fermentation broth of... 
Actinosynnema pretiosum | Endophyte | Ansamitocins | TUMOR INHIBITORS | CHEMISTRY, MEDICINAL | CHEMISTRY, APPLIED | Maytansine - chemistry | Actinomycetales - chemistry | Magnetic Resonance Spectroscopy | Maytansine - analogs & derivatives | Purification | Nuclear magnetic resonance--NMR | Fermentation | Ansamitocin | Column chromatography | Propionic acid
Journal Article
Journal Article
Archives of Biochemistry and Biophysics, ISSN 0003-9861, 2009, Volume 487, Issue 2, pp. 98 - 104
(−)-Rhazinilam was spontaneously generated from a natural product during isolation. In cultured cells, it causes microtubule bundle formation, like those... 
Rhazinilam analogs | GTP | Sedimentation assay | Tubulin | Vinblastine | Spiral morphology of tubulin polymer | (−)-rhazinilam | Glutamate | Microtubule morphology | MCF-7 human breast carcinoma cells | (-)-rhazinilam | DOLASTATIN-10 | MAYTANSINE | BRAIN TUBULIN | RHAZINILAM | INDUCED POLYMERIZATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTIMITOTIC AGENTS | COLCHICINE | BIOPHYSICS | TAXOL | BINDING | Alkaloids - pharmacology | Guanosine Triphosphate - pharmacology | Centrifugation | Humans | Lactams - chemical synthesis | Alkaloids - chemical synthesis | Antimitotic Agents - chemical synthesis | Indolizines - chemical synthesis | Tubulin - metabolism | Animals | Indolizines - chemistry | Protein Binding - drug effects | Glutamates - pharmacology | Lactams - pharmacology | Cell Line, Tumor | Antimitotic Agents - pharmacology | Microtubules - chemistry | Cell Proliferation - drug effects | Tubulin - chemistry | Tubulin - isolation & purification | Alkaloids - chemistry | Indolizines - pharmacology | Antimitotic Agents - chemistry | Lactams - chemistry | Oncology, Experimental | Analysis | Guanosine | Physiological aspects | Research | Tubulins | Polymers | Sedimentation | Cancer | rhazinilam analogs | vinblastine | microtubule morphology | tubulin | sedimentation assay | glutamate | spiral morphology of tubulin polymer
Journal Article
Cancer, ISSN 0008-543X, 03/2014, Volume 120, Issue 5, pp. 642 - 651
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 05/2014, Volume 95, Issue 5, pp. 558 - 564
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2016, Volume 22, Issue 20, pp. 5097 - 5108
Purpose: An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its... 
ANTIBODY-DRUG CONJUGATE | ONCOLOGY | CLINICAL ONCOLOGY/COLLEGE | NEU ONCOGENE | METASTATIC BREAST-CANCER | MONOCLONAL-ANTIBODY | OVARIAN-CANCER | PANCREATIC ADENOCARCINOMA | MULTIDRUG-RESISTANCE | TRASTUZUMAB EMTANSINE | AMERICAN SOCIETY | Humans | Immunoconjugates - pharmacokinetics | Macaca fascicularis | Maytansine - pharmacology | Pancreatic Neoplasms - drug therapy | Immunoconjugates - pharmacology | Topoisomerase I Inhibitors - pharmacology | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antineoplastic Agents - adverse effects | Antibodies, Monoclonal, Humanized - pharmacology | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Trastuzumab - pharmacology | Phosphorylation - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Camptothecin - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Maytansine - analogs & derivatives | Rats | Breast Neoplasms - drug therapy | Checkpoint Kinase 1 - metabolism | Animals | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Histones - metabolism | Antibody-Dependent Cell Cytotoxicity - drug effects | Camptothecin - pharmacology
Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 05/2017, Volume 16, Issue 5, pp. 315 - 337
Journal Article
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2013, Volume 40, Issue 2, pp. 259 - 270
Abstract Background Human epidermal growth factor receptor 2 (HER2) is overexpresed in 15–20% of all breast cancers. Treatment with trastuzumab has led to an... 
Hematology, Oncology and Palliative Medicine | Human epidermal growth factor receptor | Breast cancer | Lapatinib | Pertuzumab | Targeted therapy | Trastuzumab | PHASE-II | RECEPTOR | OPEN-LABEL | ANTITUMOR-ACTIVITY | COMBINATION | WEEKLY PACLITAXEL | THERAPY | ONCOLOGY | SIGNALING PATHWAY | CHEMOTHERAPY PLUS TRASTUZUMAB | Humans | Receptor, ErbB-2 - metabolism | Quinolines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Biomarkers, Tumor - metabolism | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Gene Expression Regulation, Neoplastic - drug effects | Biomarkers, Tumor - antagonists & inhibitors | Everolimus | Molecular Targeted Therapy - methods | Sirolimus - analogs & derivatives | Maytansine - analogs & derivatives | Treatment Outcome | Clinical Trials as Topic | Breast Neoplasms - drug therapy | Up-Regulation - drug effects | Disease-Free Survival | Sirolimus - administration & dosage | Maytansine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Neoadjuvant Therapy - methods | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
Journal Article